



# Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)

Mark A. Moyad<sup>1</sup>

Accepted: 16 August 2023 / Published online: 2 September 2023

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023

## Abstract

**Purpose of Review** The history of multiple weight loss medications has been a concerning paradox based on an increased cardiovascular risk despite significant reductions in adipose tissue and weight. A new class of weight loss medications could change this past narrative based on early preliminary results of cardiovascular risk (not events—still need to be determined) and weight reduction in non-diabetics that acutely competes with results achieved with bariatric surgery. The purpose of this review is to provide a comprehensive summary of the advantages and disadvantages of these newer medications, and how they could impact urology.

**Recent Findings** Weight loss of –15 to –20% compared to baseline has become plausible in the short-term and preliminary guidance to reduce acute and chronic adverse events are receiving attention. However, the cost, access, conflicts of interest, supply chain, life-long adherence issues, and the long-term diverse implications on mental and physical health when exposed to this class of medications (GLP-1 agonists) are unknown. The profound caloric reductions should also result in baseline or ongoing nutritional deficiency testing, and general and specific dietary recommendations, which could theoretically mimic some bariatric surgery pre- and post-surgical protocols but has yet to be studied. Regardless, the potential impact of these medicines within a variety of medical specialties needs clinical research.

**Summary** Current and future lifestyle interventions, dietary patterns, and medicines in the weight loss category need to be held to a paradigm whereby cardiovascular health should improve with significant weight loss without a negative impact on mental health. In urology, the ability to impact cancer risk, ED, FSD, incontinence, infertility, nephrolithiasis, and multiple other endpoints are plausible (based on bariatric surgery data) but need preliminary clinical research. Other medicines with a similar or even larger potential impact are in clinical trials, and thus, a concise overview for clinicians and researchers was needed for objective guidance. Currently, comprehensive lifestyle changes utilized with and without these medications continue to garner positive mental, physical, and legacy effects, which suggest that they are as necessary as ever in the treatment of the numerous conditions impacted by unhealthy weight gain.

**Keywords** Semaglutide · Tirzepatide · Urology · GLP-1 agonist · Bariatric surgery · Lifestyle changes · Weight loss

## Introduction

Weight loss medications, in some notable cases (fenfluramine/phentermine and sibutramine), are part of a historical dubious paradox, whereby an increased cardiovascular risk or events occurred despite significant reductions in adipose tissue [1]. A more recent concern in this category

was expressed over lorcaserin, which appeared to not only increase the risk of several different cancers [2] but had questionable mental health impacts [3]. All these past examples resulted in the removal of these options from the prescriptive marketplace. Smoking or nicotine exposure is somewhat crudely analogous to this past concerning situation since patients could lose weight or prevent gain, but it has detrimental impacts on cardiovascular and other health outcomes [4–6]. In other words, just because a product can assist with weight loss does not immediately suggest it simultaneously provides a heart or mentally healthy impact. Current and future lifestyle interventions, dietary patterns, and medicines in the weight loss category should be held to

✉ Mark A. Moyad  
moyad@med.umich.edu

<sup>1</sup> Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA

a paradigm whereby cardiovascular health (risk and events) and even all-cause morbidity and mortality should simultaneously improve with weight loss [7].

Bariatric surgery appears to have met these impressive standards [8–10], including substantial reductions in the risk and mortality of multiple cancers [10], which is why it should continue to be a primary option for those patients requiring substantial weight loss to improve a variety of health risks and outcomes. Regardless, a salubrious source of past skepticism existed over whether a non-surgical intervention could result in profound weight loss while simultaneously improving cardiovascular and all-cause risk, mortality, and their relevant clinical endpoints (myocardial infarction, stroke, cancer, etc.). Today, this historical narrative could be in flux.

Incretin mimetics were originally conceived for the treatment of type 2 diabetes via insulin production stimulation and glucose regulation, but when diabetics began to lose weight with the potential for major adverse cardiovascular event (MACE) reduction in patients with confirmed cardiovascular disease (CVD), they were then repurposed for weight reduction [11, 12]. Semaglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) agonists, which are hormones naturally produced by the human body in small dosages to slow gastric emptying and impact the brain to reduce appetite and energy intake [13–15]. GLP-1 is secreted by enteroendocrine L-cells in the small and large intestine when glucose or fat encounters the intestinal lumen. Higher concentrations of L-cells are found in the latter section of the ileum and colon. Specific cells in the nucleus tractus solitarius in the brainstem also appear to secrete GLP-1 [16•]. Interestingly, bariatric surgery with a malabsorption and restrictive component has also been found to increase GLP-1 [17], but caloric restriction (CR) without surgery has no consistent pattern from preliminary research, and some studies even suggest a reduction in this compound [18]. Moderate- and high-intensity exercise appears to acutely increase GLP-1 [19], which when combined with CR or fasting could be helpful for weight loss [20]. It is of interest many of the weight loss trials of semaglutide utilize caloric reduction and physical activity in the intervention and placebo groups [16•]. Still, one major limitation with endogenously synthesized GLP-1 is the brief plasma half-life of 1.5 to 2 min due to enzymatic elimination via dipeptidyl peptidase-4 (DPP-4) [16•]. Thus, the previous and ongoing research had led to novel GLP-1 agonists that can be exogenously delivered with longer and more sustainable half-lives. For example, semaglutide is a modified version of GLP-1 to protect it from immediate degradation and contains strong affinity to albumin with a half-life of approximately 1 week.

Tirzepatide contains an additional incretin agonist known as “gastric inhibitory polypeptide” (GIP) or “glucose-dependent insulinotropic polypeptide” [21], which could be one explanation of its preliminary greater

reduction in body weight of approximately –20% with this dual acting agonist vs semaglutide (single agonist) of –15% in non-diabetic overweight and obese patients who qualified for these medications in clinical trials. Another explanation could be the need for more phase 3 trials with tirzepatide or a head-to-head study to appreciate the mean percentage weight reduction with this medication. It should also be noted that tirzepatide was not FDA approved for weight loss at the time of manuscript submission to this journal, but the potential for approval in 2023 or early 2024 appears optimistic. This dual agonist has also brought attention to GIP, which is also secreted endogenously in humans in response to nutrient consumption, and both hormones also result in pancreatic beta-cell stimulation to release insulin in a glucose-dependent pathway [21]. GIP is secreted by K cells in the proximal portion of the small intestine. These agents represent one of the most acutely impactful weight loss interventions ever conceived and their results are superior to what has been achieved thus far in this specific and general class of medications [22], but what are the current and potential advantages and disadvantage of these novel agents?

### Acute and Chronic Adverse Effects and Medication Discontinuation Before Some Procedures

Gastrointestinal adverse effects are concerning with these medications despite being mild-to-moderate and transient especially during dose-escalation periods. For example, prescribing information for semaglutide currently lists nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache (14%), and fatigue (11%) [23]. A recent “real-life” Mayo Clinic cohort study of 175 patients found that an approximate 49% experienced adverse effects with nausea and vomiting (37%) and then diarrhea (9%) and fatigue (6%), constipation (6%), and abdominal pain (5%) less common [24]. A total of 3% discontinued the drug due to adverse effects and 9% required dose-reduction or non-dose escalation. The issue of chronic or long-term exposure to these agents has yet to be answered, except for the real observed issue of two-third weight regain from baseline after 1 year of medication cessation along with the regression of multiple metabolic markers [25••]. There is also the issue of laboratory animal studies suggesting thyroid C-cell tumor initiation in mice and rats, which was dose- and treatment-duration dependent, and how this could potentially translate to humans [23]. Currently, semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Semaglutide cessation should also occur at least 2 months—due to the extended half-life, before a planned pregnancy in females and males because of the concern for fetal injury.

Gastric emptying appears to be delayed with these agents, which raises the question of the potential of intraoperative pulmonary aspiration [26], regurgitation under anesthesia [27], upper endoscopy procedural concerns [28], and other yet to be appreciated issues. Recently, the American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting suggested patients undergoing elective procedures to temporarily discontinue GLP-1 agonists for 1 day to 1 week depending on the dosing schedule of the specific product being utilized (see consensus guideline) [29••]. This “suggestion” applies regardless of the dose, indication, or surgery/procedure. They also offer recommendations on when to consider delaying the elective procedure based on gastrointestinal symptoms, and recommendations of what to consider even if no symptoms are occurring, but the medication was not withheld. This guidance statement also acknowledges preliminary research, which suggests that gastric emptying issues appear to decrease with long-term utilization [29••, 30].

A separate expert multidisciplinary expert consensus manuscript was also recently published on how to prevent and manage gastrointestinal issues in patients on GLP-1 agonists [31••]. This manuscript is a preliminary guide on dealing with the most common adverse effects of these medications. Again, these issues are prevalent regardless of the half-life, duration, or route of exposure (oral/subcutaneous). Gastrointestinal (GI) side effects are usually temporary and occur often during dose-escalation periods and when the maintenance dosage is achieved it is less prevalent in incidence and severity. Some of the many dietary suggestions proffered to decrease the intensity of GI issues include the following (see the publications for more detailed information):

- Consume smaller portion meals more often, eat slowly, only when hungry, and feeling of satiety should cause eating cessation
- Sitting or standing after a meal (avoid lying down)
- Do not consume food near bedtime, be less active after eating, and avoid drinking with a straw
- Low-fat diets and water-based salubrious foods (soups, gelatin etc.) are more ideal
- Avoid high-fat and processed or refined foods
- Try to limit or avoid sweets, spices, dressings, and canned food
- Maintain a food diary to determine personal food triggers and relievers of adverse effects

There are also added recommendations for those with nausea (ginger-based drinks, etc.), vomiting (hydrate, smaller meals, etc.), diarrhea (hydration, electrolyte beverages, avoid high fiber and sugar alcohols, etc.), or constipation [31••]. It should also be noted that weight loss

has currently not been correlated with the extent of GI side effects with these newer GLP-1 agonists [32, 33], which may be another advantage compared to some older medications in this class [34], but this issue requires more analysis. Separately, the recent FDA approval of semaglutide in adolescents (age 12 or older) suggests the short-term safety of this and potentially other newer agents in this class are still notable [23, 35]. In general, side effects in teenagers from a phase 3 trial occurred early and began to dissipate over time [36]. In adults semaglutide 2.4 mg once weekly was approved for weight management in patients with a BMI of 27 or more who have at least one or more weight-associated health issues, or in patients with a BMI of 30 or more [23, 37]. In teens it was approved for aged 12 and older who are at the 95th percentile or higher for sex and age (obesity)-based on growth chart criteria from the Centers for Disease Control (CDC) [35]. In adults and teens the FDA approval also includes the language to include a caloric reduction meal plan and increased physical activity in addition to the medication for optimal efficacy.

### **Appetite, Cravings, Energy Intake, Food Preferences, Satiation, Taste, and Addictions?**

The old adages of “calories in versus out” or “calorie intake versus caloric burn” although often criticized do have some merit regarding dramatic weight reduction. This was identified in bariatric surgery patients in whom the procedure has short- and long-term success with greater sustained reductions in energy intake [38•]. Interestingly, energy or caloric reductions of more than 50–66% from baseline can be observed initially post-surgery, but over the next several years this percentage tends to decrease to less than 50%, and after 10 years there appears to be tremendous latitude in patient energy intake ranging from less than 10 to 45% reductions [38•, 39]. Again, some of the largest reductions in weight in men and women over short and long periods occur in those able to achieve the largest caloric reductions along with appropriate macronutrient intakes. Some of the largest caloric reductions in the first year are predictive of long-term success, and the mean weight loss appears greatest after year 1 compared to any other year up to a decade later. It appears over time that most patients cannot sustain such profound caloric restrictions, and this is reflective in the percentage weight changes from baseline. For example, after 1 year of follow-up in a notable study men and women lost approximately 24% and 26% of their baseline weight, but after 10 years of follow-up this was reduced to 15% and 17%, respectively [38•]. However, the plus or minus standard deviation around these mean reductions from baseline in the first- to the tenth-year post-surgery was approximately

9–12%. This would in part (not fully) explain why weight regain occurs in many patients as well as one reason a small percentage of patients do not experience significant weight loss over time, which is why other competitive non-surgical options would also be beneficial, or even perhaps some select patients could synergistically utilize a procedure with a medication. Additionally, with increasing age and reductions in weight there is a reduction in basal metabolic rate (BMR) with an increase in appetite, which partly explains why some partial weight regain over time is the rule and not the exception regardless of the past diet or surgical intervention studied [40–42].

Preliminarily, the dramatic acute caloric reduction situation has also been observed regarding the newer GLP-1 medications [43]. Appetite, energy intake, and fat mass reductions occur including in those with type 2 diabetes, but remarkably there has been minimal published overall on the quantity and quality of calories impacted upon medication initiation, continuation, or cessation. For example, on a subcutaneous low dose (1 mg) of semaglutide a 24% reduction in total caloric intake was noted at 12 weeks from baseline [44]. A trial of standard dosage of semaglutide for weight loss observed a –47.1% mean energy intake versus –18.6% with placebo at week 20 from baseline with increases in satiation [45]. In a study of type 2 diabetics on oral semaglutide (14 mg) after 12 weeks, energy intake was reduced by approximately 39% versus placebo (–1217 cal) [46]. Thus, preliminary data suggests that profound caloric reduction occurs with higher oral and injectable dosages of these medications. It appears reasonable to predict that 25–50% energy intake decreases with the conventional weight loss dosages of the GLP-1 agonists. Whether or not this can continue long term is unknown. One interesting differential impact of these agents is the ability for those without diabetes or simply less insulin resistance to experience larger reductions in weight [16•].

Another preliminary observation is the impact of these medications on food preferences or cravings. A recent systematic review of 12 GLP-1 agonist studies meeting the inclusion criteria ( $n=445$ ) found appetite and craving reductions, food preference and taste changes, and altered gastric emptying were noteworthy [47]. In the STEP 5 trial of semaglutide at 104 weeks there was a significant reduction in the penchant for salt, spicy, dairy, and starchy foods [48]. Perhaps another mechanism of interest is the ability of these agents to impact foods or behaviors associated with greater caloric intake or adipose tissue storage. Thus, it is plausible that some addictive behaviors or self-medicating tendencies with certain foods and other substances could be favorably impacted. Recent laboratory evidence suggests that GABA neurotransmission could be affected, which could result in a reduction in alcohol intake or other addictive behaviors [49]. It is for this reason clinicians may not only be able to

prevent smoking cessation weight gain on these agents, but the desire for tobacco intake itself, if future studies suggest a benefit in this area. This would be one area of research interest in urology or other specialties where immediate smoking cessation could provide a morbidity and mortality advantage (bladder cancer treatment, etc.).

## Adipose Tissue (Fat Mass) vs Lean Muscle Mass Lost and Resistance Exercise?

Body weight changes appear to be primarily the result of fat mass reduction with GLP-1 agonists, although lean muscle mass loss also occurs. A subgroup of the STEP 1 study (95 on semaglutide and 45 on placebo) utilized DEXA (dual-energy X-ray absorptiometry) imaging to monitor body mass after 68 weeks [50•]. Total and regional fat mass decreases from baseline were found with semaglutide along with total lean mass (kg), but the percentage of lean body mass in relation to total body mass increased. For example, the kilogram change in total fat mass was approximately –10.40 with semaglutide vs –1.17 with placebo, and for total lean body mass it was –6.92 vs –1.48. Thus, the fat to lean mass loss was a ratio of 1.5 vs 0.79 and suggests that participants on placebo experienced a greater loss in lean versus fat mass.

Regardless of the DEXA mathematics involved, it has been appreciated that with any acutely effective weight loss method, including bariatric surgery, the loss of some lean muscle mass or fat free mass (20–40%) is expected, but there tends to be more substantial loss of fat mass [51]. Why lean muscle mass is lost universally in these situations harbors many theories, but it appears that muscle protein synthesis (MPS) is not impaired; rather, an accelerated muscle proteolysis occurs. This would continue to suggest aerobic physical activity with an emphasis on regular resistance exercise, and appropriate (not extreme) protein intakes could be of benefit, but this has not been adequately studied with the newer GLP-1 agonists as with multiple other caloric reduction scenarios. Obesity harbors more muscle mass, but of less quality vs healthy weight individuals, and weight loss with resistance exercise is an opportunity to improve quality, maintain strength, and potentially preserve greater lean mass during profound or even moderate weight reduction. Macronutrient intake in the bariatric literature also appears to suggest protein intake maintained or appropriately improved is a greater predictor of sustained weight loss [38•, 52], and greater intake of carbohydrates and/or alcohol could be associated with a greater weight gain post-procedure [53]. Still, greater overall energy or caloric consumption continues to be correlated with less than substantial weight loss after these procedures [54], and how this relates to GLP-1 agonist sub-optimal weight changes needs further investigation.



## BMI Controversial Indication

Whether or not a patient qualifies for these newer weight loss medications is based on BMI-based criteria [23]. This is controversial because BMI alone is an inconsistent measure of overweight and obesity [55], and recently major medical groups such as the American Medical Association (AMA) are requesting reevaluation or additional evaluations of this parameter based on a variety of issues [56]. There is also the concept of BMI healthy but metabolically unhealthy especially with aging and co-morbidities, which suggest that certain individuals are prone to losing muscle and bone, but simultaneously gain adipose tissue, which may not appreciably alter their total weight or BMI [57]. A reliance on additional cardiovascular and metabolic markers, and the potential use of waist circumference (WC), waist-to-hip ratio (WHR), or other BMI-adjunct parameters, is paramount. Where do these other individuals fit in the paradigm for the new weight loss medications? BMI benefit appears more correlative at the larger values ( $\geq 30$ ) and this is one advantage of such a rapid simplistic measurement. However, since it cannot establish where the distribution of adipose tissue resides, and it cannot precisely define morbidity and mortality risk, it appears imperative not only to incorporate other risk markers in these other individuals, but also to advocate for more trials to address the issue of optimal medication candidacy.

## Cardiovascular Risk and Event Reduction? SELECT Trial

In patients with type 2 diabetes on GLP-1 agonists the evidence continues to accumulate over cardiovascular marker improvement as well as a reduction in events [16•]. This is encouraging based on the forementioned dubious history of effective weight loss drugs eventually removed from the market. In patients without diabetes there is also the preliminary suggestion of favorable changes in cardiovascular markers from blood pressure, glucose, lipids, inflammation, and WC [16•, 58, 59]. Even in normotensive patients systolic (approximately  $-5$  mm Hg) and diastolic ( $-2.5$  mm Hg) reductions were observed. An improvement in physical function and mood has also been preliminarily cited, but short- and long-term diverse mental and physical health impacts need to be better clarified. Also, whether medication changes, cessation, dosage reduction of other conventional medicines, and reductions in microvascular and macrovascular issues occur need more research. For example, bariatric surgery is currently well known to impact not only risk parameters, but also medication utilization rates, microvascular and macrovascular events, and all-cause morbidity and mortality [8–10, 60].

SELECT was the name of a well-known trial of selenium and/or vitamin E for the prevention of prostate cancer that did not demonstrate benefit, but rather the potential for harm [61]. However, SELECT is also the name of a potentially transformative trial (in a positive or negative manner) with semaglutide on the impact of cardiovascular events in non-diabetic patients ( $n = 17,605$ ) with overweight or obesity with documented cardiovascular disease and a history of a cardiovascular event [62]. Arguably, this trial should report interim results in 2023–2024, and is the first major test of whether these medications change cardiovascular outcomes and event rates.

## Cost, Conflict of Interest, Compounding, Competition (Head-to-Head), and Priority Review Voucher Programs

The cost and access issues of these potentially life-long medications without knowledge of long-term adverse events are concerning [63•], as is the potential for conflict of interest [64], and even the recent concern over the safety of some compounding pharmacies formulating these medications [65]. Compounded medications are not FDA-approved, and the safety or impact of these drugs is not validated by the agency. The FDA has received some safety signals with some forms of compounded semaglutide. On an optimistic note, there are numerous phase 3 trials ongoing of various diverse drugs in the GLP-1 agonist and associated classes, which in the next few years if long-term safety prevails should add to a keen and intense competition pool [63•]. This could impact not only availability, but also insurance coverage, access issues, out-of-pocket costs, and an eventual generic lower cost option(s).

The intense competition to become the medication of choice in the weight loss milieu cannot be understated. Older weight loss medications from different classes achieved approximately 5% (plus or minus several percentage points) of weight loss over placebo, which places the current results with the newer GLP-1 agonists in a unique efficacy category [66]. Semaglutide has been tested against an older GLP-1 agonist, liraglutide (approved for weight loss in 2014), and after 68 weeks mean body weight changes of  $-15.8\%$  versus  $-6.4\%$  significantly favored semaglutide [22]. Although, tirzepatide appears to have achieved greater weight loss versus semaglutide when indirect studies are analyzed [67, 68]. Interestingly, a recent phase 3 trial (NCT05822830) sponsored by Eli Lilly known as “SURMOUNT-5” was announced at the time of this manuscript’s submission, which will utilize semaglutide versus tirzepatide in non-diabetic adults ( $n = 700$ ) with a primary endpoint of a percentage change in body weight from baseline over 72 weeks [69]. This study is expected to be completed in late 2024. Of further interest, Eli Lilly recently appeared to utilize a “priority review voucher,” which cost over 100 million US dollars

in order to accelerate the review of tirzepatide for weight loss [70]. Priority review vouchers are not created to increase the probability of FDA acceptance, but rather to move up in que, or shorten the time interval before a decision is proffered [71].

### **Dietary Deficiency/Insufficiency, Laboratory Testing, and Supplementation?**

Bariatric surgery contains multiple clinical guidelines concerning the potential for nutrient deficiency or insufficiency and procedures involved in repletion [72, 73]. No such standards exist yet with these novel medications except for the previously mentioned 2023 dietary expert guidance for preventing or managing gastrointestinal issues [31••]. This is partially understandable based on their recent approval, but at the same time concerning since the weight loss achieved initially competes with bariatric surgery. Issues of malnutrition with these medications could be an ongoing and future concern [74]. What should protein or macronutrient intake, in general, be when initiated and maintained on these medications? What about nutrient testing? It would appear standard to ingest a daily multivitamin, pay attention to macronutrient intakes, and ideally meet with a dietician and other health professionals on regular intervals, but again all these issues remain at an embryonic stage, and would appear to require immediate attention, awareness, and research.

### **Urologic Opportunities and Concerns (Bariatric Surgery Lessons and Comparisons)**

The potential to investigate the benefits and limitations of these medications in a variety of specialties, including urology, abounds. The known improvements in some urologic conditions with bariatric surgery should also be appreciated and provide guidance for what could be researched, expected, or even dissimilar with the newer long-acting GLP-1 agonists.

Interestingly, at the time of this manuscript's submission there has been essentially minimal data published on the impact of GLP-1 agonists on diverse urologic disease risk or outcomes. Bariatric surgery results could provide a partial guide of potential expectations. For example, the reduction in the risk of multiple cancers was mentioned [10], including some urologic cancers in specific patient populations [75], and cancer-related mortality also appears to be impacted [76]. Minimal past laboratory data exists to suggest that some GLP-1 agonists could inhibit prostate cancer proliferation [77]. It would also be of interest as to whether aggressiveness, progression, recurrence, or urologic cancer mortality could be impacted, as well as reducing the conventional medicine issues exacerbated by unhealthy weight

status. Preventing the impact of smoking cessation weight gain for example [5], especially in a patient already dealing with an unhealthy weight status after certain urologic procedures and treatments, such as cystectomy or intravesical therapy could be an avenue of interest.

Sexual function and incontinence should be other areas of interest based on recent data. For example, a summary of 14 studies ( $n = 508$ ) found a mean testosterone increase of 156.3 pg/ml (95% CI 84.78–227.86;  $p < 0.0001$ ) in men receiving bariatric surgery [78]. The reported increases found in this analysis varied from less than 100 to 350 pg/ml. Improvements in erectile function, desire, intercourse, and overall satisfaction were also noted. A meta-analysis in women found a 76% decrease in female sexual dysfunction (FSD), and improvements in the female sexual function index (FSFI) in all domains, except pain, from 16 observational studies ( $n = 953$ ) [79]. Significant short- and long-term benefits in improving urinary continence (stress, urge, mixed) have already been noted for male and female patients undergoing bariatric surgery [80, 81]. It would also be of interest in patients needing various urologic surgery procedures if significant weight loss before or after the procedure would further improve surgical outcomes. Would BPH outcomes improve with medications, or with minimally invasive procedures when substantial weight loss is accomplished [82–84]? There is also the issue of male and female fertility and whether weight loss via bariatric procedures has resulted in improved fertility parameters and outcomes [85–88]. In fact, the impact of GLP-1 agonists on sperm quality and quantity is unknown, and currently pregnancy or considering pregnancy is reason for discontinuation of these medications.

Nephrolithiasis risk after bariatric surgery is concerning, regardless of the procedure utilized, although biliopancreatic diversion with duodenal switch (BPD-DS) appears to be associated with the highest risk versus Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in some notable observational series [89]. Age, comorbidities, and stone history prior to the procedure could also impact risk, but one could argue that weight loss of these magnitudes could reduce the risk of stone disease in some patients [90]. Interestingly, at the time of the submission of this manuscript there was a dearth of data on GLP-1 agonists and kidney stone risk or recurrence. Nephrolithiasis has not been associated with semaglutide or other novel GLP-1 agonists in past phase 3 trials, but in general these trials are of a short duration. Could this be an advantage over bariatric surgery, at least in the short term, or has this issue or awareness not been recognized until now? Additionally, one of the more notable postoperative issues in bariatric surgery are urinary tract infections (UTIs), and this risk is impacted by a variety of factors [91, 92]. Again, a dearth of data exists in GLP-1 agonist literature in terms of UTI risk (increase, decrease,

no impact) before, during, and after profound weight loss is achieved. The list of opportunities in determining the true effects of GLP-1 agonists on urologic risks and outcomes appear boundless and should be determined if these agents remain a mainstay of weight management.

## Conclusion

Weight loss, at least in the first 2 years of semaglutide or tirzepatide utilization, is unprecedented in medicine with a non-surgical option. It is imperative that clinicians and researchers throughout medical specialties become accustomed to the evolving potential advantages and disadvantages of these products within their respective disciplines [29••, 31••], and even from case series [93]. What clinically occurs with long-term utilization of these agents from side effects to efficacy is unknown, but thus far the ability to reduce weight, and cardiovascular risk appears impressive enough to consider studying their impacts, even observationally, in urologic settings. What should also be appreciated is the pipeline of these and related medications. Results suggest that similar or even greater weight reduction to injectable semaglutide or tirzepatide is occurring at this moment [63•]. Oral orforglipron (– 15% weight loss) [94] and once-weekly subcutaneous retatrutide are two of the many examples [95]. For example, retatrutide, a triple agonist (GLP-1, GIP, and glucagon receptor), recently demonstrated the most profound percentage weight loss from baseline of any trial to date with an impressive – 24.2% after 48 weeks in the 12-mg dosage group. Drug delivery advances and options also recently occurred in a phase 3 trial of high-dose (50 mg) oral semaglutide, which appeared to provide weight loss identical to their injectable product [96]. Perhaps we need to visualize these novel medications indifferently if they indeed remain on the market for the long term. It was not long ago the idea of controlling blood pressure, cholesterol, or glucose and reducing morbidity and mortality with a potentially lifelong medication would have seemed innovative and today it has become an untenable evidence-based foundation of preventive medicine. So, why not weight loss medication? Could this be the moment they prevail or will compliance [97], or another physical or mental health issue alter the fate of these newer medications [98], somewhat akin to what was forementioned with some past notable medications?

Finally, what will be the fate of diet and exercise if the situation remains optimistic for these medications? Lifestyle or behavioral changes impact some of the same established cardiovascular parameters, and they can enhance conventional treatment outcomes, reduce the dosage of some medications, and improve mental health outcomes [7]. Could this be the case with the weight loss medications? It

is the hope of this author, especially if safety and efficacy continue, and cost and access issues profoundly change. In the meantime, lifestyle changes from aerobic to resistance exercise in conjunction with proper dietary changes are also what appear to result in enhanced efficacy and reduced adverse effects from these novel medications. Thus, lifestyle changes and traditional proven medications will be as critical as ever, because they also have legacy effects on their own, even when reduced or discontinued that need to be embraced [99–103], just as much as these novel pharmacologic weight loss interventions, which as of this moment have not demonstrated similar such effects when medication cessation occurs.

**Author Contributions** Mark A. Moyad, MD, MPH conceived and wrote the main manuscript and procured, reviewed, and inserted the references.

## Compliance with Ethical Standards

**Competing Interests** Dr. Moyad was a quality control consultant for Max International Beauty (Cosmetics).

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by the author.

## References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
  - Of major importance
1. Przegalinski E, Witek K, Wydra K, Kotlinska JH, Filip M. 5-HT<sub>2c</sub> receptor stimulation in obesity treatment: orthosteric agonists vs. allosteric modulators. *Nutrients*. 2023;15(6):1449. <https://doi.org/10.3390/nu15061449>.
  2. Food & Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market: potential risk of cancer outweighs the benefits. Accessed 1 Jul 2023. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market>.
  3. DiNicolantonio JJ, Chatterjee S, O’Keefe JH, Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. *Open Heart*. 2014;1(1)e000173. <https://doi.org/10.1136/openhrt-2014-000173>.
  4. Garcia-Fernandez G, Krotter A, Gonzalez-Roz A, Garcia-Perez A, Secades-Villa R. Effectiveness of including weight management in smoking cessation treatments: a meta-analysis of behavioral interventions. *Addict Behav*. 2023;140:107606. <https://doi.org/10.1016/j.addbeh.2023.107606>.
  5. Tian J, Venn A, Otahal P, Gall S. The association between quitting smoking and weight gain: a systemic review and meta-analysis of prospective cohort studies. *Obes Rev*. 2016;17(10):1014. <https://doi.org/10.1111/obr.12448>.

6. Okorare O, Evbayekha EO, Adabale OK, Daniel E, Ubokudum D, Olusiji SA, Antia AU. Smoking cessation and benefits to cardiovascular health: a review of literature. *Cureus*. 2023;15(3):e35966. <https://doi.org/10.7759/cureus.35966>.
7. Moyad MA. Preventing lethal prostate cancer with diet, supplements, and Rx: heart healthy continues to be prostate healthy and “first do no harm” part I. *Curr Urol Rep*. 2018;19:104. <https://doi.org/10.1007/s11934-018-0846-4>.
8. Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. *PLoS Med*. 2020;17(7):e1003206. <https://doi.org/10.1371/journal.pmed.1003206>.
9. Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174772 participants. *Lancet*. 2021;397(10287):1830–41. [https://doi.org/10.1016/S0140-6736\(21\)00591-2](https://doi.org/10.1016/S0140-6736(21)00591-2).
10. Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. *Int J Mol Sci*. 2023;24(7):6192. <https://doi.org/10.3390/ijms24076192>.
11. Urquhart S, Willis S. Long-acting GLP-1 receptor agonists: findings and implications of cardiovascular outcomes trials. *JAAPA*. 2020;33(8):19–30. <https://doi.org/10.1097/01.JA.0000669452.63883.45>.
12. Xu D, Nair A, Sigston C, Ho C, Li J, Yang D, et al. Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in nondiabetic populations. *Cardiovasc Ther*. 2022;2022:6820377. <https://doi.org/10.1155/2022/6820377>.
13. Cifuentes L, Camilleri M, Acosta A. Gastric sensory and motor functions and energy intake in health and obesity-therapeutic implications. *Nutrients*. 2021;13(4):1158. <https://doi.org/10.3390/nu13041158>.
14. Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ. Intestine-selective reduction of *Gcg* expression reveals the importance of the distal gut for GLP-1 secretion. *Mol Metab*. 2020;37:100990. <https://doi.org/10.1016/j.molmet.2020.100990>.
15. Holst JJ, Orskov C, Hartmann B, Deacon CF. Posttranslational processing of proglucagon and postsecretory fate of proglucagon products. *Front Diabetes*. 1997;13:24–48. <https://doi.org/10.1159/000194728>.
16. ● Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. *Postgrad Med*. 2022;134(suppl1):5–17. <https://doi.org/10.1080/00325481.2022.2147326>. **One of the best cumulative objective reviews of the different phase 3 trials results utilizing semaglutide.**
17. Smith EP, Polanco G, Yaqub A, Salehi M. Altered glucose metabolism after bariatric surgery: what’s GLP-1 got to do with it? *Metabolism*. 2018;83:159–66. <https://doi.org/10.1016/j.metabol.2017.10.014>.
18. Tacad DKM, Tovar AP, Richardson CE, Horn WF, Krishnan GP, Keim NL, Krishnan S. Satiety associated with calorie restriction and time-restricted feeding: peripheral hormones. *Adv Nutr*. 2022;13(3):792–820. <https://doi.org/10.1093/advances/nmac014>.
19. Hu M, Kong Z, Shi Q, Nie J. Acute effect of high-intensity interval training versus moderate-intensity continuous training on appetite-regulating gut hormones in healthy adults: a systematic review and meta-analysis. *Heliyon*. 2023;9(2):e13129. <https://doi.org/10.1016/j.heliyon.2023.e13129>.
20. Deru LS, Chamberlain CJ, Lance GR, Gipson EZ, Bikman BT, Davidson LE, et al. The effects of exercise on appetite-regulating hormone concentrations over a 36-h fast in healthy young adults: a randomized cross-over study. *Nutrients*. 2023;15(8):1911. <https://doi.org/10.3390/nu15081911>.
21. touchREV Endocrinol. Tirzepatide: a novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. 2022;18(1):10–9. <https://doi.org/10.17925/EE.2022.18.1.10>.
22. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sorrig R, et al for the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 Randomized Clinical Trial. *JAMA*. 2022;327(2):138–50. <https://doi.org/10.1001/jama.2021.23619>.
23. Wegovy (semaglutide injection 2.4 mg) Prescribing Information. Accessed 1 Jul 2023 at <https://www.novo.pi.com/wegovy.pdf>.
24. Ghusen W, De la Rose A, Sacoto D, Campos A, Feris F, Hurtado MD, Acosta A. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. *JAMA Network Open*. 2022;5(9):e2231982. <https://doi.org/10.1001/jamanetworkopen.2022.31982>.
25. ●● Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. *Diabetes Obes Metab*. 2022;24(8):1553–64. <https://doi.org/10.1111/dom.14725>. **One of the only studies to examine what happens when medication cessation occurs—two thirds of weight lost was regained within the first year of discontinuation.**
26. Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. *Can J Anaesth*. 2023. <https://doi.org/10.1007/s12630-023-02440-3>.
27. Gulak MA, Murphy P. Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. *Can J Anaesth*. 2023. <https://doi.org/10.1007/s12630-023-02521-3>.
28. Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. *J Clin Anesth*. 2023;87:111091. <https://doi.org/10.1016/j.jclinane.2023.111091>.
29. ●● Joshi GP, Abdelmalak BB, Weigel WA, Soriano SG, Harbell MW, Kuo CI, et al. for the American Society of Anesthesiologists (ASA) Task Force on Preoperative Fasting. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. Accessed 1 Jul 2023 at <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative>. **One of the only current guidelines recommendations for surgical teams dealing with patients on these novel medications.**
30. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. *Diabetes Obes Metab*. 2018;20(3):610–9. <https://doi.org/10.1111/dom.13120>.
31. ●● Gorgojo-Martinez JJ, Mazquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. *J Clin Med*. 2023;12:145. <https://doi.org/10.3390/jcm12010145>. **One of the only comprehensive guides published to date on how to prevent and manage some of the most common side effects of these weight loss medications.**
32. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingway I, et al. Gastrointestinal tolerability of once-weekly



- semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. *Diabetes Obes Metab.* 2022;24(1):94–105. <https://doi.org/10.1111/dom.14551>.
33. Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, et al. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. *BMJ Open Diabetes Res Care.* 2020;8(2):e001706. <https://doi.org/10.1136/bmjdcrc-2020-001706>.
  34. Zhou F, Jiang L, Jiamei G, Fan Y, Pan Q, Tianlian L, et al. Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes. *Ther Adv Chronic Dis.* 2023;14:20406223231161516. <https://doi.org/10.1177/20406223231161516>.
  35. FDA approves once-weekly Wegovy® injection for the treatment of obesity in teens aged 12 and older. Accessed 1 Jul 2024 at <https://www.novonordisk-us.com/media/news-archive/news-details.html?id=151389>.
  36. Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen OK, et al. for the STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. *N Engl J Med.* 2022. 387(24):2245–57. <https://doi.org/10.1056/NEJMoa2208601>.
  37. FDA approves new drug treatment for chronic weight management, first since 2014. Accessed 1 Jul 2023 at <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014>.
  38. Kanerva N, Larrson I, Peltonen M, Lindroos A-K, Carlsson LM. Changes in total energy intake and macronutrient composition after bariatric surgery predict long-term weight outcome: findings from the Swedish Obese Subjects Study. *Am J Clin Nutr.* 2017;106(1):136–45. <https://doi.org/10.3945/ajcn.116.149112>. **The main manuscript and supplementary index provide a rare glimpse into the quantity and quality of caloric intakes, which impact short and long-term weight loss after bariatric surgery.**
  39. Giusti V, Theytaz F, Di Vetta V, Clarisse M, Sutter M, Tappy L. Energy and macronutrient intake after gastric bypass for morbid obesity: a 3-y observational study focused on protein consumption. *Am J Clin Nutr.* 2016;103(1):18–24. <https://doi.org/10.3945/ajcn.115.111732>.
  40. Reichmann MTF, Duarte A, Ivano F, Campos ACL. Evolution of the basal metabolic rate after Roux-en-Y gastric bypass: a systematic review and meta-analysis. *Updates Surg.* 2023. <https://doi.org/10.1007/s13304-023-01523-6>.
  41. Moehlecke M, Blume CA, Rheinheimer J, Trindade MRM, Crispim D, Leitao CB. Early reduction in energy expenditure and successful weight loss after Roux-en-Y gastric bypass. *Surg Obes Relat Dis.* 2017;13(2):204–9. <https://doi.org/10.1016/j.soard.2016.08.027>.
  42. Monnier L, Schlienger J-L, Colette C, Bonnet F. The obesity treatment dilemma: why dieting is both the answer and the problem? A mechanistic overview. *Diabetes Metab.* 2021;47(3):101192. <https://doi.org/10.1016/j.diabet.2020.002>.
  43. Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. *Diabetes Care.* 2023;46(5):1–7. <https://doi.org/10.2337/dc22-1710>.
  44. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. *Diabetes Obes Metab.* 2017;19(9):1242–51. <https://doi.org/10.1111/dom.12932>.
  45. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. *Diabetes Obes Metab.* 2021;23(3):754–62. <https://doi.org/10.1111/dom.14280>.
  46. Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. *Diabetes Obes Metab.* 2021;23(2):581–8. <https://doi.org/10.1111/dom.14255>.
  47. Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. *Diabetes Metab Syndr Obes.* 2023;16:575–95. <https://doi.org/10.2147/DMSO.S387116>.
  48. Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Obesity (Silver Spring). Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. 2023;31(3):703–15. <https://doi.org/10.1002/oby.23673>.
  49. Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. *JCI Insight.* 2023. <https://doi.org/10.1172/jci.insight.170671>.
  50. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. for the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med.* 2021;384(11):989–1002. <https://doi.org/10.1056/NEJMoa2032183>. **Supplementary table 5 provides a unique look at the impact of this medication on fat and lean muscle mass compared to placebo.**
  51. Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. *Adv Nutr.* 2017;8(3):511–9. <https://doi.org/10.3945/an.116.014506>.
  52. de Souza Vilela DL, da Silva A, Pinto SL, Bressan J. Relationship between dietary macronutrient composition with weight loss after bariatric surgery: a systematic review. *Obes Rev.* 2023;24(6):e13559. <https://doi.org/10.1111/obr.13559>.
  53. Reid RER, Oparina E, Plourde H, Andersen RE. Energy intake and food habits between weight maintainers and regainers, five years after Roux-en-Y gastric bypass. *Can J Diet Pract Res.* 2016;77(4):195–8. <https://doi.org/10.3148/cjdrp-2016-013>.
  54. Moslehi N, Kamali Z, Golzarand M, Sakak FR, Mirmiran P. Association between energy and macronutrient intakes and weight change after bariatric surgery: a systematic review and meta-analysis. *Obes Surg.* 2023;33(3):938–49. <https://doi.org/10.1007/s11695-022-06443-9>.
  55. Bray GA, Beyond BMI. *Nutrients.* 2023;15(10):2254. <https://doi.org/10.3390/nu15102254>.
  56. American Medical Association (AMA) Press Release. AMA adopts new policy clarifying role of BMI as a measure in medicine. Accessed 1 Jul 2023 at <https://www.ama-assn.org/press-center/press-releases/ama-adopts-new-policy-clarifying-role-bmi-measure-medicine>.
  57. Mathus-Vliegen EMH. Obesity and the elderly. *J Clin Gastroenterol.* 2012;46(7):533–44. <https://doi.org/10.1097/MCG.0b013e31825692ce>.
  58. Gao X, Hua X, Wang X, Xu W, Zhang Y, Shi C, Gu M. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. *Front Pharmacol.* 2022;13:935823. <https://doi.org/10.3389/fphar.2022.935823>.
  59. Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. *J Clin Med.* 2023;12(3):772. <https://doi.org/10.3390/jcm12030772>.

60. Adams TD, Meeks H, Fraser A, Davidson LE, Holmen J, Newman M, et al. Long-term all-cause and cause-specific mortality for four bariatric surgery procedures. *Obesity* (Silver Spring). 2023;31(2):574–85. <https://doi.org/10.1002/oby.23646>.
61. Klein EA, Thompson IA Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA*. 2011;306(14):1549–56. <https://doi.org/10.1001/jama.2011.1437>.
62. Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. for the SELECT Study Group. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. *Obesity* (Silver Spring). 2023;31(1):111–22. <https://doi.org/10.1002/oby.23621>.
63. Jeon E, Lee KY, Kim K-K. Approved anti-obesity medications in 2022 KSSO Guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon. *J Obes Metab Syndr*. 2023;32(2):106–20. <https://doi.org/10.7570/jomes23032>. **One of the best summaries of the weight loss medication pipeline, which is replete with potential future options if efficacy and safety can be sustained.**
64. Novo Nordisk spent \$11 million on Ozempic promotion. Accessed on 1 Jul 2023 at: <https://finance.yahoo.com/video/novo-nordisk-spent-11-million-155418308.html>.
65. Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. Accessed on 1 Jul 2023 at <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss>.
66. Jung HN, Jung CH. The upcoming weekly tides (semaglutide versus tirzepatide) against obesity: STEP or SURPASS. *J Obes Metab Syndr*. 2022;31(1):28–36. <https://doi.org/10.7570/jomes22012>.
67. le Roux CW, Hankosky ER, Wang D, Malik R, Yu M, Hickey A, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison. *Diabetes Obes Metab*. 2023. <https://doi.org/10.1111/dom.15148>.
68. Azuri J, Hammerman A, Aboalhasen E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. *Obesity* (Silver Spring). 2023;31(6):1510–3. <https://doi.org/10.1002/oby.23752>.
69. Clinicaltrials.gov. A study of tirzepatide (LY3298176) in participants with obesity or overweight with weight related comorbidities (SURMOUNT-5). Accessed on 1 Jul 2023 at: <https://classic.clinicaltrials.gov/ct2/show/NCT05822830?term=NCT05822830&draw=2&rank=1>.
70. Block J. Eli Lilly to use priority review voucher for Mounjaro weight loss indication. <https://seekingalpha.com/news/3961462-eli-lilly-priority-review-voucher-mounjaro-weight-loss-indication>.
71. Sarpatwari A, Kesselheim AS. Efficacy of the priority review voucher program. *JAMA*. 2016;315(15):1660–1. <https://doi.org/10.1001/jama.2016.0386>.
72. Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the surgical weight loss patient 2016 update: micronutrients. *Surg Obes Relat Dis*. 2017;13(5):727–41. <https://doi.org/10.1016/j.soard.2016.12.018>.
73. O’Kane M, Parretti HM, Pinkney J, Welbourn R, Hughes CA, Mok J, et al. British Obesity and Metabolic Surgery Guidelines for perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery—2020 update. *Obes Rev*. 2020;21(11):e13087. <https://doi.org/10.1111/obr.13087>.
74. Blum D. An extreme risk in taking Ozempic: malnutrition: the diabetes medication has gained attention for its dramatic weight loss effects—but doctors worry that it can go too far. Accessed on 1 Jul 2023 at: <https://www.nytimes.com/2023/04/21/well/eat/ozempic-side-effects-malnutrition.html>.
75. Desai D, Singhal S, Koka J. Evaluating the correlation of bariatric surgery and the prevalence of cancers in obese patients: a study of the National Inpatient Sample Database. *Cureus*. 2022. 14(4):e23976. <https://doi.org/10.7759/cureus.23976>.
76. Aminian A, Wilson R, Al-Kurd A, Tu C, Milinovich A, Kroh M, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. *JAMA*. 2022;327(24):2423–33. <https://doi.org/10.1001/jama.2022.9009>.
77. Nomiya T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. *Diabetes*. 2014;63(11):3891–905. <https://doi.org/10.2337/db13-1169>.
78. Malczak P, Wysocki M, Pisarska-Adamczyk M, Strojek J, Rodak H, Lastovetskiy I, et al. Influence of bariatric surgery on erectile dysfunction—a systematic review and meta-analysis. *Obes Surg*. 2023;33(6):1652–8. <https://doi.org/10.1007/s11695-023-06572-9>.
79. Loh HH, Shahar MA, Loh HS, Yee A. Female sexual dysfunction after bariatric surgery in women with obesity: a systematic review and meta-analysis. *Scand J Surg*. 2022;111(1):14574969211072396. <https://doi.org/10.1177/14574969211072396>.
80. King WC, Hinerman AS, Subak LL. Seven-year durability of improvements in urinary incontinence after Roux-en-Y gastric bypass and sleeve gastrectomy. *JAMA Netw Open*. 2022. 5(12):e2246057. <https://doi.org/10.1001/jamanetworkopen.2022.46057>.
81. Lee Y, Yu J, Tikkinen KAO, Pedziwiatr M, Major P, Aditya I, et al. The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis. *BJU Int*. 2019;124(6):917–34. <https://doi.org/10.1111/bju.14829>.
82. Muller RL, Gerber L, Moreira DM, Andriole Jr G, Hamilton RJ, Fleshner N, et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. *Eur Urol*. 2013;63(6):111es 5–1121. <https://doi.org/10.1016/j.eururo.2013.02.038>.
83. Nosrati F, Nikoobakht MR, Oskouie IM, Rahimdoost N, Inanloo H, Abolhassani M, et al. Does significant weight loss after bariatric surgery affect sexual function and urinary symptoms? An Iranian Study. *Obes Surg*. 2023. <https://doi.org/10.1007/s11695-023-06717-w>.
84. Stefanova I, Currie AC, Newton RC, Albon L, Slater G, Birnie A, et al. Systematic review and meta-analysis of the impact of bariatric surgery on lower urinary tract symptoms in males. *Obes Surg*. 2021;31(7):3151–8. <https://doi.org/10.1007/s11695-021-05403-z>.
85. Lee Y, Dang JT, Switzer N, Yu J, Tian C, Birch DW, Karmali S. Impact of bariatric surgery on male sex hormones and sperm quality: a systematic review and meta-analysis. *Obes Surg*. 2019;29(1):334–46. <https://doi.org/10.1007/s11695-018-3557-5>.
86. Gao Z, Liang Y, Yang S, Zhang T, Gong Z, Li M, Yang J. Bariatric surgery does not improve semen quality: evidence from a meta-analysis. *Obes Surg*. 2022;32(4):1341–50. <https://doi.org/10.1007/s11695-022-05901-8>.
87. Moxthe LC, Sauls R, Ruiz M, Stern M, Gonzalvo J, Gray HL. Effects of bariatric surgeries on male and female fertility: a systematic review. *J Reprod Infertil*. 2020;21(2):71–86. <https://pubmed.ncbi.nlm.nih.gov/32500010/>.
88. Alibhai KM, Churchill IF, Vause T, Lochnan HA. The impact of bariatric surgery on assisted reproductive technology outcomes: a systematic review. *J Obstet Gynaecol Can*. 2022;44(8):915–23. <https://doi.org/10.1016/j.jogc.2022.04.010>.
89. Laurenus A, Sundbom M, Ottosson J, Naslund E, Stenberg E. Incidence of kidney stones after metabolic and bariatric surgery—data from the Scandinavian Obesity Surgery Registry.

- Obes Surg. 2023;33(5):1564–70. <https://doi.org/10.1007/s11695-023-06561-y>.
90. Thongprayoon C, Cheungpasitporn W, Vijayvargiya P, Anthonont P, Erikson SB, Ren Fail. The risk of kidney stones following bariatric surgery: a systematic review and meta-analysis. 2016;38(3):424–30. <https://doi.org/10.3109/0886022X.2015.1137186>.
  91. Helmen ZM, Helm MC, Helm JH, Nielsen A, Kindel T, Higgins R, et al. Predictors of postoperative urinary tract infection after bariatric surgery. *Obes Surg*. 2018;28(7):1950–4. <https://doi.org/10.1007/s11695-017-3095-6>.
  92. Arafat M, Norain A, Burjonrappa S. Characterizing bariatric surgery utilization and complication rates in the adolescent population. *J Pediatr Surg*. 2019;54(2):288–92. <https://doi.org/10.1016/j.pedsurg.2018.10.089>.
  93. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin—a case series. *Ther Adv Psychopharmacol*. 2023. <https://doi.org/10.1177/20451253231165169>.
  94. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. for the GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. *N Engl J Med*. 2023. <https://doi.org/10.1056/NEJMoa2302392>.
  95. Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. for the Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. *N Engl J Med*. 2023. <https://doi.org/10.1056/NEJMoa2301972>.
  96. Knop FK, Aroda V, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2023. [https://doi.org/10.1016/S0140-6736\(23\)01185-6](https://doi.org/10.1016/S0140-6736(23)01185-6).
  97. Terhune C for Reuters. Exclusive: most patients using weight loss drugs like Wegovy stop within a year, data show. Accessed on 11 Jul at: <https://www.reuters.com/business/healthcare-pharmaceuticals/most-patients-using-weight-loss-drugs-like-wegovy-stop-within-year-data-show-2023-07-11/>.
  98. Reuters and NBC News. EU investigates Ozempic and weight-loss drug Saxenda after reports of suicidal thoughts. Accessed 11 Jul 2023 at: <https://www.nbcnews.com/news/world/eu-investigates-ozempic-saxenda-suicidal-thoughts-reported-rcna93552>.
  99. Hartmann-Boyce J, Theodoulou A, Oke JL, Butler AR, Bastounis A, Dunnigan A, et al. Long-term effect of weight regain following behavioral weight management programs on cardiometabolic disease incidence and risk: systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes*. 2023;16(4):e009348. <https://doi.org/10.1161/CIRCOUTCOMES.122.009348>.
  100. Theodoulou A, Hartmann-Boyce J, Gorenberg J, Oke JL, Butler AR, Bastounis A, et al. Weight regain and mental health outcomes following behavioural weight management programmes: a systematic review and meta-analysis. *Clin Obes*. 2023. 13(3):e12575. <https://doi.org/10.1111/cob.12575>.
  101. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. *Lancet*. 374(9702):1677–86. [https://doi.org/10.1016/S0140-6736\(09\)61457-4](https://doi.org/10.1016/S0140-6736(09)61457-4).
  102. Vinas Esmel E, Naval Alvarez J, Sacanella ME. The legacy effect in the prevention of cardiovascular disease. *Nutrients*. 2020;12(11):3227. <https://doi.org/10.3390/nu12113227>.
  103. Johnson JL, Slentz CA, Ross LM, Huffman KM, Kraus WE. Ten-year legacy effects of three eight-month exercise training programs on cardiometabolic health parameters. *Front Physiol*. 2019;10:452. <https://doi.org/10.3389/fphys.2019.00452>.
- Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.